| HS Code | 354403 |
| Product Name | Banhuan Baidu Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Api Type | Veterinary grade active pharmaceutical ingredient |
| Grade | Veterinary grade |
| Physical Form | Fine crystalline powder |
| Color | White to off-white |
| Odor | Characteristic or odorless |
| Solubility | Soluble in suitable solvents; aqueous solubility depends on salt form |
| Available Dosage Forms | Tablets, injections, capsules, powders, granules, premix, solutions |
| Purity Assay | ≥99.0% (HPLC, dry basis) |
| Loss On Drying | ≤0.5% |
| Heavy Metals | ≤20 ppm |
| Residual Solvents | Complies with ICH/VICH limits |
| Storage Conditions | Store in tightly closed containers in a cool, dry place, protected from light |
| Shelf Life | 24 months when stored under recommended conditions |
| Packaging | Sealed double polyethylene bags inside fiber drums or customized |
| Regulatory Compliance | Complies with veterinary pharmacopoeia standards |
As an accredited Banhuan Baidu Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Banhuan Baidu Tablets Veterinary Grade API packaged in 25 kg drums; suitable for tablets, injections, capsules, powders, granules, premix, solutions. |
| Container Loading (20′ FCL) | 20′ FCL: Palletized drums/cartons, secured and sealed, ensuring safe, compliant loading for veterinary-grade pharmaceutical API. |
| Shipping | Shipping for Banhuan Baidu Tablets Veterinary Grade API follows strict hazardous-material and cold-chain protocols. Product is sealed in moisture-proof, tamper-evident containers, then placed in UN-certified outer packaging. Documentation includes veterinary API certificates and safety data sheets. Shipments are tracked with temperature-monitored logistics, ensuring stability and regulatory compliance during global transit. |
| Storage | Store in a cool, dry, well-ventilated area at controlled room temperature (below 25°C). Keep container tightly closed and protected from light, moisture, and direct sunlight. Avoid contact with oxidizing agents and incompatible substances. Ensure adequate ventilation, maintain clean conditions, and follow veterinary pharmaceutical handling procedures. Use within manufacturer’s stated shelf life. |
| Shelf Life | Shelf life is typically 24 months when stored in original sealed containers, protected from light, moisture, and heat. |
For oral tablet manufacture, Banhuan Baidu Tablets Veterinary Grade API is handled as a hygroscopic dried extract rather than as a free-flowing synthetic crystalline material. The first production decision is whether direct compression can maintain die-fill uniformity at an active loading above 8% w/w; dry extract lots with broad particle size distribution have shown segregation under high-speed rotary compaction, so wet granulation becomes the default route when the formulation requires 10–30% w/w of the API in the final core. The applicable standards are Ph. Eur. 0478, USP <1217>, USP <701>, USP <905>, and 21 CFR 210/211 for finished pharmaceutical release. In a 600 L V-blender, the extract is blended with microcrystalline cellulose, lactose monohydrate, and crospovidone at 20–25 rpm for 25–35 min, followed by wet granulation with 50–70% v/v ethanol or purified water. The wet mass is dried in a fluid-bed dryer at 45–55°C until loss on drying is ≤ 3.0%, milled through a 16-mesh screen, and lubricated with magnesium stearate for only 3–5 min to avoid over-lubrication. Compression on a rotary tablet press runs at 12–25 kN, with target hardness 50–80 N and disintegration time ≤ 15 min under USP <701> at 37°C in 0.1 M HCl. Terminal product types include uncoated tablets, film-coated tablets, and oral boluses. The critical processing window is RH 60%; if the extract moisture exceeds 5.0% before compression, pre-drying at 40–50°C for 2–4 h is required to restore flow and hardness uniformity.
Sterile injectable production with Banhuan Baidu Tablets Veterinary Grade API is constrained by bacterial endotoxin control and membrane fouling, not merely by solubility. The applicable standards are Ph. Eur. 0520, Ph. Eur. 2.6.14, USP <1>, USP <85>, and EU GMP Annex 1 for all post-sterilization operations. The solution strength is fixed between 10 mg/mL and 50 mg/mL of dried extract equivalent, depending on the endotoxin challenge of the incoming lot; published data for this specific product at higher concentrations is limited. Dissolution is performed in Water for Injections at 20–30°C with pH adjustment to 5.0–7.0 using dilute hydrochloric acid or sodium hydroxide. The bulk solution is then passed through an activated-carbon or depth filter to reduce endotoxin load, followed by a 0.45 µm prefilter and two 0.22 µm sterilizing-grade PVDF filters in series. Terminal sterilisation at 121°C for 15 min is used only when thermal stability of the extract is confirmed; otherwise sterile filtration with aseptic filling is required. The failure mode observed in production-scale campaigns is progressive flux loss across the sterilizing filter when high-molecular-weight polysaccharide fractions exceed the lot-specific threshold; filter capacity should not be extrapolated from small-scale tests. Terminal finished dosage forms are injectable solutions for parenteral administration in amber glass vials or ampoules, released only under a marketing authorization that covers the injectable route.
Capsule filling with Banhuan Baidu Tablets Veterinary Grade API follows Ph. Eur. 0016 and USP <711> for shell integrity and dissolution; the dried extract is milled to D90 ≤ 0.5 mm, blended at 12–25% w/w of total fill weight, and filled on a tamping-pin capsule filler into hard gelatin or HPMC capsules for oral veterinary administration, with content uniformity controlled under USP <905>. Fill mass moisture is maintained below 5.0% because higher moisture softens gelatin shells and increases fill weight variability on capsules produced at commercial speed.
For drinking-water medication in food-producing animal operations, the API must be converted into a water-dispersible granule that does not settle before the stock solution reaches the drinker line. Compliance is governed by EU Regulation 2019/6 for authorized veterinary medicinal products and by EU GMP Part I; granule particle size is verified by Ph. Eur. 2.9.12 sieve analysis and USP <811> powder fineness. The addition ratio of the dried extract in the final granule is kept between 20–40% w/w, with dextrose monohydrate or lactose as the carrier and povidone K30 as the binder at 2–5% w/w of dry mass. In a fluid-bed granulator with a 1200 mm Wurster insert, the extract-carrier blend is agglomerated using purified water at an inlet temperature of 50–65°C, a spray rate of 80–150 g/min, and an atomization pressure of 1.5–2.5 bar. The end point is a final granule moisture of ≤ 2.5% and a bulk density of 0.45–0.65 g/mL. The reconstitution requirement is that a 10 g/L solution at 20°C passes through a 180 µm screen within 3 min without visible sediment. Terminal finished product types include 100 g, 500 g, and 1 kg sachets or plastic pails for on-farm stock solution preparation. The main process limit is hygroscopic recovery: if the extraction batch has a residual moisture above 5.0% before granulation, the fluid-bed spray cycle must be lengthened, otherwise agglomerates collapse during drying and the reconstitution time increases beyond the 3 min release criterion.
In medicated feed premix operations, Banhuan Baidu Tablets Veterinary Grade API is introduced by geometric dilution inside a ribbon mixer rather than as a single addition at the top of the mixer. The relevant regulatory anchors are Regulation (EU) 2019/4 for medicated feed, 21 CFR 225.10–225.50 for medicated feed mill cGMP, and ISO 6497 for sampling of animal feeding stuffs. The active extract is formulated into a premix at 2–10% w/w, and the premix is subsequently incorporated into complete feed at 1–5 kg/tonne depending on the authorized dose, target species, and carryover limits. The production sequence uses a 1000 L ribbon mixer; the first dilution is prepared by mixing the API with 10 kg of wheat middlings or ground corncob for 10–15 min, followed by stepwise enlargement with the remaining carrier until the full batch is reached. Mixing after final addition continues for 15–20 min; homogeneity is confirmed by ten sampling points with a coefficient of variation ≤ 5.0% for the active marker. Particle size of the premix is controlled to D90 ≤ 250 µm to avoid segregation during pneumatic conveying. Terminal product types include 5 kg, 10 kg, and 25 kg multi-wall paper or film bags, and satellite premix packs for feed mills. The critical operational boundary is carryover: residual dust in the ribbon mixer discharge gate can cross-contaminate the next non-medicated batch, so a 10 kg wheat middlings flush is run after each campaign and flush material is either discarded or used only in the next medicated batch of the same API and dose.
Oral solution and suspension manufacture with Banhuan Baidu Tablets Veterinary Grade API is determined by pH-dependent solubility and microbial challenge rather than simple dissolution rate. The compliance references are Ph. Eur. 0672 for oral liquids, USP <1151> for pharmaceutical dosage forms, and VICH GL5 for stability testing of new veterinary medicinal products. The dry extract is first dispersed as a 20% w/v stock concentrate; the final oral liquid is adjusted to 1–5% w/v dry extract equivalent in a citrate or phosphate buffer system at pH 4.5–5.5. Downstream mixing is completed in a 500 L high-shear disperser at 3000–5000 rpm for 20–30 min, followed by two-pass homogenization at 200–300 bar to reduce particle size to D90 ≤ 20 µm. The finished suspension is filled into high-density polyethylene bottles with tamper-evident closures. Terminal product types include oral drench solutions, oral suspensions, and liquid top-dress formulations for authorized veterinary indications in food-producing animals. The main operational limitation is preservative compatibility: some phenolic preservatives show reduced free concentration in botanical extract solutions; benzalkonium chloride is evaluated case-by-case due to potential ionic complexation at pH above 6.0. If the pH drops below 4.0, sedimentation is no longer the primary failure mode; extract constituents may undergo pH-dependent degradation, shifting the stability-indicating assay outside specification during accelerated storage at 40°C/75% RH under VICH GL5 conditions. In this case the batch should be re-buffered before homogenization rather than adjusted after filling.
Competitive Banhuan Baidu Tablets Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Banhuan Baidu Tablets Veterinary Grade API is released as a bulk active ingredient for downstream processing into tablets, injections, capsules, powders, granules, premix, and solutions. The designation “Banhuan Baidu Tablets” identifies the reference oral solid dosage form; the API itself is not a finished veterinary medicine and must not be administered without further manufacturing, quality control, and, for parenteral products, terminal sterilization or aseptic filling. Each batch is supplied with a certificate of analysis covering identity, assay, loss on drying, residue on ignition, heavy metals, residual solvents, and microbial limits. Because the material is intended for multiple routes of administration, the receiving manufacturer carries the burden of dosage-form-specific process validation under the applicable veterinary GMP framework, such as China’s Veterinary Drug GMP regulations and, where export-oriented, the relevant elements of EU GMP Annex 2 for active pharmaceutical ingredients or ICH Q7 for good manufacturing practice.
Release specifications are partitioned into identity, purity, physical, and microbial control groups. Identification is typically confirmed by high-performance liquid chromatography with diode-array detection against a qualified reference standard; because Banhuan Baidu may contain multiple marker compounds, an assay based on a single marker is insufficient to control lot-to-lot consistency. Assay limits are established in the receiving dossier and should be expressed as a percentage of the labeled content on the dried basis. Loss on drying is controlled because moisture above 5.0% w/w can depress glass transition in dry granulation and increase the risk of sticking during tablet compression under high-speed rotary tooling. Residue on ignition and elemental impurities are evaluated using pharmacopoeial methods; for international submissions, elemental impurity control follows USP <232> and USP <233> or ICH Q3D, with the route-specific permitted daily exposure selected by the target species and final dose. Residual solvent reporting follows USP <467> or the corresponding veterinary pharmacopoeia method when ethanol or other process solvents are employed. The API is non-sterile at release; therefore, the certificate of analysis reports total aerobic microbial count, total combined yeast and mold count, and absence of Salmonella and Escherichia coli per the relevant veterinary monograph. If the product is destined for injection, the receiving site must add depyrogenation and bioburden-reduction steps because the bulk API is not supplied endotoxin-free.
| Dosage form | Critical parameter | Control boundary | Reference method or equipment |
|---|---|---|---|
| Tablets by direct compression | Flow function coefficient | >4 | Schulze ring shear test; USP <905> for weight variation |
| Injections | Bioburden before filtration | <100 CFU/g | USP <61>, USP <62>, USP <85> |
| Premix | Assay coefficient of variation after mixing | <5.0% | Mixer discharge sampling; final feed concentration within ±10% of label claim |
| Capsules and powders | Granule moisture after drying | <5.0% w/w or below stability limit | Loss on drying; moisture sorption isotherm |
For solid dosage forms, particle-size distribution is the principal determinant of blend homogeneity, flow, and dissolution. Laser diffraction data on the API should report D10, D50, and D90 values with a defined dispersion pressure and refractive index. When D90 exceeds 250 µm, the probability of segregation in low-dose premixes increases sharply; when D90 is below 45 µm, electrostatic adhesion to stainless-steel contact surfaces and hopper bridging may become controlling. The specific surface area, measured by nitrogen adsorption or air-permeation, influences dissolution rate in tablet and capsule matrices. A bimodal distribution can be acceptable for premix applications if the carrier is matched to the fine fraction, but it is generally unfavorable for direct compression because the fine fraction preferentially coats larger carrier particles and may generate flow variability. Bulk density and tapped density should be reported to allow calculation of the Hausner ratio and compressibility index; values above 1.25 or compressibility above 25% signal that glidant addition or granulation may be required before high-speed encapsulation or tableting. These measurements define the mechanical operating window of the receiving solid-dosage line.
Direct compression is the most sensitive operation among the listed routes because it requires simultaneous flow, compaction, and ejection performance without a granulation step to correct defects. On rotary tablet presses equipped with multi-tip tooling and precompression, the blend must maintain a flow function coefficient above 4 in a Schulze ring shear tester; below this value, die fill variability produces weight variation that can exceed USP <905> acceptance criteria. Capping and lamination are controlled by the compaction profile: the ratio of precompression force to main compression force is commonly set between 5% and 15%, and the punch dwell time must be sufficient for plastic deformation of the API-excipient matrix. Because Banhuan Baidu API may behave as a brittle material, microcrystalline cellulose or spray-dried lactose is used to impart plastic character; however, the addition level is constrained by tablet size and target-species palatability. Lubricant concentration is critical: magnesium stearate at 0.5% to 1.0% w/w reduces ejection force, but over-lubrication above 1.5% w/w can coat the active surface and delay dissolution in low-dose tablets. Hydraulic compaction data from a uniaxial press or single-station press do not fully predict performance on a high-speed rotary press; therefore, final settings should be confirmed on the same type of 10-station or 16-station equipment used for commercial batches.
Solution and injection manufacture imposes additional controls not required for oral powders. The API must first be subjected to solubility screening across water for injection, ethanol, propylene glycol, and pH-adjusted buffers. If the compound has limited aqueous solubility, co-solvent systems or pH modifiers must be selected using compatibility data generated with the actual commercial batch. Published data for Banhuan Baidu API in injectable form are limited; therefore, filter compatibility, recovery, and extractables studies must be performed under ICH Q3C residual solvent guidance and USP <85> bacterial endotoxins test methodology. The non-sterile API cannot be rendered sterile by filtration alone if the solution bioburden exceeds the filter retention capacity; typical veterinary parenteral processing uses 0.22 µm membrane filtration followed by terminal sterilization, or aseptic filling where the active is heat-sensitive. The receiving manufacturer must validate the maximum holding time for the compounded solution because oxidation or hydrolysis can shift assay potency and increase subvisible particulate counts measured under USP <788>. For multi-dose veterinary injections, an approved preservative is required unless the product is intended for immediate use; selection of preservative must be supported by antimicrobial effectiveness testing in the final container.
Premix and medicated-feed applications require the active to be distributed onto a solid carrier, usually calcium carbonate, rice hulls, or corn cob granules. The main processing risk is active loss through adsorption onto porous carrier surfaces, which can produce low assay recovery despite acceptable bulk blend uniformity. To separate the two failure modes, sampling must follow a structured protocol at the mixer discharge and after transfer to the feed line. The coefficient of variation for assay at the mixer discharge is often required to remain below 5.0% for a homogeneous premix, while the final medicated feed concentration is expected to fall within ±10% of label claim under current veterinary premix guidance. If the active-to-carrier particle-size ratio exceeds 10:1, segregation during transfer becomes a dominant concern; the use of anti-segregation baffles or a post-mix granulation step may be required. Ribbon mixer and paddle mixer performance differ: a ribbon mixer may provide adequate distribution in 10–15 min at moderate speed, but over-mixing can break the carrier and generate fines that hold active via electrostatic attraction rather than simple surface adhesion. The resulting assay variation is not corrected by increased mixing time alone.
For capsule, powder, and granule presentations, the processing boundary is set by granulation endpoint and moisture rather than by direct compression flow. Low-shear planetary mixers, high-shear wet granulators, and fluid-bed dryers each produce different granule density and porosity. If the API is moisture-sensitive, dry granulation by slugging or roller compaction is preferred; if wet granulation is unavoidable, the binder solution addition rate should be controlled so that final granule moisture by loss on drying remains below the limit established in the laboratory stability study. Drying temperature must not exceed the thermal degradation threshold identified by forced-degradation testing; without published data for this specific product, an initial upper bound of 60°C is a conservative default for thermally labile botanical actives until experimental data show otherwise. Granules entering a capsule filler should have a Hausner ratio below 1.25 and a friability not exceeding 1.0% to avoid filling-weight drift. Powders for oral administration should be dispensed in unit-dose sachets or bottles with desiccant when the moisture sorption isotherm shows mass gain greater than 2.0% at 60% relative humidity. These limits are derived from powder-technology practice and may be tightened by the receiving manufacturer’s process capability analysis.
Banhuan Baidu Tablets Veterinary Grade API differs from a crude botanical powder in that it is controlled by a multi-parameter release specification and intended for formulation into discrete dosage units. A crude powder may be sold with only macroscopic identification and total ash, whereas the veterinary API is expected to demonstrate chromatographic reproducibility, defined solvent residue, and microbial control sufficient for pharmaceutical processing. It differs from a single-entity chemically synthesized API in the complexity of its analytical fingerprint: retention-time alignment, relative peak areas, and baseline separation from matrix co-extractives must be addressed before assay integration. This creates a practical constraint in method transfer; a high-performance liquid chromatography method that is acceptable for a synthetic drug with one active peak may be insufficient for Banhuan Baidu because co-eluting compounds can bias potency results under slightly different column temperatures or mobile-phase pH. The receiving manufacturer should therefore perform a forced-degradation and specificity study under ICH Q2(R1) conditions before accepting the assay as stability-indicating. The multi-dose-form applicability also distinguishes this product from proprietary finished tablets: the API is sold for further manufacturing and requires the customer to hold the necessary veterinary drug manufacturing authorization and to assign the withdrawal period, target species, and label claims based on its own registration file.
The product should be stored in tightly closed containers under conditions validated by the supplier’s stability data. Unless the immediate container is moisture-proof, the receiving facility should quarantine and re-test after exposure to relative humidity above 60% or after prolonged storage in unconditioned warehouses. The API is not approved for use in food-producing animals unless the receiving manufacturer establishes a complete tissue residue and withdrawal period file under the applicable regulatory authority; the bulk product label should not be interpreted as a therapeutic claim. Avoid combining the API with strong oxidizing agents or, in solution, with incompatible acid-sensitive excipients unless buffering is demonstrated in the compounding record. Because the material is a multi-component botanical active, batch-to-batch variation in the relative abundance of minor peaks may occur even when the primary marker assay is within specification; that variation should be tracked by multivariate statistical process control rather than by a single potency value. No sterile claim, depyrogenation claim, or particle-size certification should be inferred from the general release document unless the specific parameter is listed and tied to a method identifier on the certificate of analysis.
